Scientific Program
Wed
Thu
Fri
Sat
Wednesday, May 7, 2025
Breast Cancer
| Welcome Adress of the Hosts and Greeting Words J.-U. Blohmer and J. Sehouli | |
Presidential Lecture | |
| New Strategies for the Treatment of ER+/HER2-Endocrine-resistant Breast Cancer M. Goetz | |
Live Surgery from 2 operating rooms |
Moderation: M. Karsten, F. Reyal
- Total Breast Reconstruction with AFT
- Conversion from Implant to AFT
- Various Techniques of BCS and SNB
- Gender-affirming Breast Surgery
- Other Breast Surgeries
Surgeons: J.-U. Blohmer, O. Camara,
R. Khouri, A. Piatkowski, C. Neeb,
R. Reinemer, J. K. Wagner, C. Weiler
| Lunch Break | |
Symposium With kind support of Daiichi Sankyo and AstraZenecaSpotlight ADCs: An Update for Breast and Gynaecological CancersChairs: J. Sehouli and J.-U. Blohmer
| |
| Chairs: S. Kümmel and V. Kiver | |
Presidential Lecture | |
| Role of Surgery in Breast Cancer Treatment J.-U. Blohmer | |
Trials | |
| The Most Relevant Clinical Trials (European Perspective, Global Perspective) S. Kümmel | |
Lectures | |
| Invasive Lobular Carcinoma (ILC): Translational Data S. Oesterreich | |
| Invasive Lobular Carcinoma (ILC): Clinical Data M. Karsten | |
| Endocrine Resistance: Translational Data A. Lee | |
| Discussion S. Oesterreich, M. Karsten, A. Lee | |
| Coffee Break | |
| Chairs: J.-U. Blohmer and S. Oesterreich | |
Lectures | |
| The Role of Germline Pathogenic Mutations and Endocrine Sensitivity S. Yadav | |
| Germline Mutations: Digital Tools for Pathologists and Physicians D. Speiser | |
| TNBC: Identifying New Biomarkers for Treatment Escalation and De-escalation R. Leon Ferre | |
Symposium with kind support of StemlineExtending Endocrine Treatment by Overcoming ESR1 MutationsChair: J.-U. Blohmer
| |
| End of program | |
Please note: On Thursday, there will be more lectures in the parallel session Breast Cancer II.
CMC Crash Course
01:45 to 03:45 pm
Biomarker in Targeted Therapies and Management of Toxicity (ADCs) in Endometrial, Ovarian, and Cervical Cancer
E. I. Braicu, K. Moore, R. Chekerov, D. Rieke, M. Shahi
CMC Master Course
04:00 to 06:00 pm
Surgical and Topographic Anatomy in Ovarian Cancer and Surgical Complication Management in Gynecological Oncology
J. Sehouli, W. Cliby, C. Fotopoulou, J. Neymeyer
Thursday, May 8, 2025 I/II
Breast Cancer Session II
| Chair: J.-U. Blohmer | |
Hottest Topics in Clinical Routine and ResearchBreast Surgery | |
| Surgical Aspects under TNBC F. Reyal | |
| BCS vs. ME; R0 vs. R1 Resektion C. Weiler | |
| Free Flap or AFT in Breast Reconstruction R. Khouri | |
| Implant or AFT in Breast Reconstruction A. Piatkowski | |
Panel Discussion | |
| Breast Surgery 1 C. Weiler, R. Khouri, A. Piatkowski | |
Breast Surgery and Around | |
| Gender-affirming Surgery R. Reinemer | |
| Risk-reducing Surgery: How to Avoid Pitfalls J.-U. Blohmer | |
| PROs: How to Bring them into Clinical Practice M. Karsten | |
Panel Discussion | |
| Breast Surgery 2 R. Reinemer, J.-U. Blohmer, M. Karsten | |
Video Session | |
| Breast Cancer Surgery | |
| End of this Session / Begin of Lunch Break | |
Parallel to the Session »Redefining Limits« (Gynecologic Oncology)
Thursday, May 8, 2025 II/II
Cervical Cancer, Endometrial Cancer, and other Solid Tumors
Redefining Limits: Interdisciplinary Approaches in Complex Cancer
Surgery in the Management of Gynecological Malignancies
Chairs: J. Sehouli, R. Armbrust, C. L. Langstraat, S. C. Dowdy
Opening Lectures | |
| Principles and Scheduling of Complex Oncological Surgery in an Interdisciplinary and Interprofessional Setting J. Sehouli | |
| Options and Limits of Blood Management for Complex Surgeries L. Kaufner | |
Session 1 | |
| Case Report: Cerebellar Metastasis in an Ovarian Cancer Patient A. Miranda | |
| Brain Metastases – Is there a Role for Surgery in Gynecological Cancer? P. Vajkoczy | |
| Oligometastatic Disease in Ovarian Cancer – Sporadic or Clinically Meaningful? K. Pietzner | |
| Discussion | |
Session 2 | |
| Case Report: Granulosa Cell Tumor Relapse and Major Liver Resection I. Sterner | |
| Beyond Borders: Joint Cases of Hepatobiliary and Gynecological Cancer Surgeons W. Schöning | |
| Discussion | |
| Coffee Break | |
Session 3 | |
| Case Report: Enterovaginal Fistula Incervical Cancer Relapse M. Beck | |
| Radical Pelvic Exenteration – Borders and Limiting Factors A. Kumar | |
| Complex Reconstruction of the Bladder and Ureter J. Neymeyer, M. Z. Muallem | |
| Discussion | |
Session 4 | |
| Case Report: Sarcoma with Bladder and Rectum Infiltration E. Roser | |
| Principles of Sarcoma and Vessel Surgery R. Öllinger | |
| Discussion | |
Session 5 | |
| Case Report: Pleural Effusion and Pleural Carcinomatosis M. Lee | |
| Role of Thoracic Surgery in Lung and Pleural Metastases J. Neudecker | |
| Discussion | |
Session 6 | |
Video Session
| |
| Lunch Break | |
Symposium With kind support of GlaxoSmithKlineNew Treatment Options for First-line Endometrial Cancer – More Complexity and More OpportunitiesChair: J. Sehouli
| |
Cervical CancerChairs: W. Lichtenegger and N. Abu-Rustum | |
Presidential Lecture | |
| Revolution in Cervical Cancer Management, Radical Hysterectomy, Simple Hysterectomy, or Cone Biopsy in Early Stage N. Abu-Rustum | |
Trials | |
| The Most Relevant Clinical Trials (ENGOT, GOG and more) – 10 Minutes Around the World R. Armbrust | |
Hottest Debates in Clinical Routine and ResearchPrimary Local Advanced Cervical Cancer | |
| Neoadjuvant Chemotherapy M. McCormack | |
| Primary Radio-Immuno-Chemotherapy F. Mehrhof | |
| Primary Surgery, When, How, When Not? M. Z. Muallem | |
Panel Discussion | |
| What is the Best Therapy Algorithm? W. Lichtenegger, N. Abu-Rustum, M. McCormack, F. Mehrhof, M. Z. Muallem, B. Monk | |
| Coffee Break | |
Endometrial CancerChairs: K. Pietzner and A. Mariani | |
Presidential Lecture | |
 Endometrial Cancer Management: Options and Limits to Substitute Chemotherapy?N. Colombo | |
Trials | |
| The Most Relevant Clinical Trials (ENGOT, GOG and More) – 10 Minutes Around the World L. Chinczewski | |
Hottest Debates in Clinical Routine and Research | |
| Primary Chemo-Immunotherapy Plus/Minus PARP Inhibitor M. R. Mirza | |
| What are the Predictive Markers for Response to PARP? E. I. Braicu | |
| What is the Best Medical Therapy in the Relapse Setting (Endocrine, Immuno After Immuno, Chemo after Chemo, PARP after PARP, Role of ADC)? A. Wahner-Hendrickson | |
| ITC in Endometrial Cancer A. Mariani | |
Panel Discussion | |
| What is the Best Therapy Algorithm? K. Pietzner, A. Mariani, M. R. Mirza, E. I. Braicu, A. Wahner-Hendrickson | |
| End of Program | |
CMC Master Course I
01:30 to 03:30 pm
How to Avoid and How to Solve Problems in Breast Surgeries
J.-U. Blohmer, O. Camara, R. Reinemer, S. Paepke, and guests
CMC Master Course II
03:45 to 05:45 pm
Basics of Breast Reconstruction – Implant, Flaps, and AFT
J.-U. Blohmer, O. Camara, R. Reinemer, S. Paepke, and guests
Friday, May 9, 2025
Ovarian Cancer
Live Surgery from 3 operating rooms |
Moderation: R. Chekerov, S. Dowdy, W. Cliby, M. Renz
- En-bloc Resection
- Peritonectomy
- Nerve-sparing Techniques
- Lymph Node Dissection
- ICG Techniques
- Perioperative Management
Surgeons: J. Sehouli, R. Armbrust, C. Fotopoulou, M.Z. Muallem
★★★
During Live Surgery:
- The Most Challenging Case of the Year
A. Miranda - Scientific Highlight of the Year: Exclusive Charité-Mayo Data
| Lunch Break | |
Symposium With kind support of AbbVieAntibody-Drug Conjugates: Facing Platinum | |
| Chairs: S. Dowdy and J. Sehouli | |
Presidential Lecture | |
| Primary Surgery or Interval Surgery – What is the Current Evidence? S. Mahner | |
Trials | |
| The Most Relevant Clinical Trials (ENGOT, GOG and more) – 10 Minutes Around the World T. Arndt | |
Hottest Debates in Clinical Routine and Research | |
| Maintenance Therapy: But what? J. Ledermann | |
| BRCA/HRD-adjusted Surgery in Primary OC? M. Renz | |
| What is the Best Therapy in the HRD Group? B. Monk | |
Panel Discussion | |
| What is the Best Therapy Algorithm? S. Dowdy, J. Sehouli, J. Ledermann, M. Renz, B. Monk | |
| Coffee Break | |
| Chairs: W. Cliby and R. Chekerov | |
Debate | |
Relapsed Ovarian Cancer: Salvage Surgery or Neoadjuvant Therapy?
| |
LecturesPlatinum or Chemo Resistance? Time to Change the Definition and the Treatment Algorithm | |
| ADCs G. Konecny | |
| Rechallenge of Previous Therapy J. Grabowski | |
| Chemotherapy-free Approaches S. Banerjee | |
| Best Supportive Care Only! E. Roser | |
| Palliative Surgery C. Fotopoulou | |
| Discussion | |
| End of Program | |
CMC Master Course
04:30 to 06:30 pm
Prerehabilitation, Fast-track Rehabilitation, ERAS, Minimally Invasive Complication Management
S. Dowdy, A. Kumar, J. Sehouli, M. Lee
Saturday, May 10, 2025
Cross Talk and More
| Chairs: A. Ulrich and S. Nasser | |
Presidential Lecture | |
| How We Can Improve Women’s Health N. Muntean  | |
Lectures | |
| Screening for Cardiovascular Diseases in Women U. Landmesser | |
| Biomarker in Targeted Therapies: Yesterday, Today, Tomorrow K. Moore | |
| How to Translate Guidelines into Regions with Limited Resources D. Cibula | |
| Chairs: D. Cibula and J.-U. Blohmer, P. Wimberger | |
Learning Across the Diseases | |
| Endocrine Therapy: What is the Code in Breast Cancer, What in Gynecological Malignancies? | |
| |
| |
| |
| PARP Inhibitors: What is the Code in Gynecologcial Malignancies, What in Breast Cancer, What in Other Solid Tumors and Who are the Best Candidates? | |
| |
| |
| |
| Checkpoint Therapy: What is the Code in Gynecologcial Malignancies, What in Breast Cancer, What in Other Solid Tumors? | |
| |
| |
| |
Lunch Break During Lunch Break: | |
| ADCs: What is the Code in Gynecologcial Malignancies, What in Breast Cancer, What in Other Solid Tumors? | |
| |
| |
| |
Lectures | |
| Leveraging AI to Decode and Replicate Cellular Architecture: A Vision for the Future S. Quake | |
| Harnessing AI for Predicting Patient Outcomes in Oncology: Current Insights and Challenges J. N. Kather | |
New Options in the Management of Malignant Ascites
| |
Closing Session | |
| 3 Best Posters: Discussion and Acknowledgment Poster Awards | |
| Closing Words and Farewell J.-U. Blohmer and J. Sehouli | |
| End of Program | |
CMC Cadaver Course
08:00 to 12:00 pm
Gynecology
M. Z. Muallem, A. Miranda, T. Jöns, O. Camara, C. Langstraat
Status: 03/2025; May be subject to change.